Medifast, Inc, through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands.
Read More…
Industry, Sector and Symbol
Industry Miscellaneous food preparations & kindred products
Sub-IndustryPersonal Products
SectorConsumer Staples
Phone410-581-8042
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$501 million
Profitability
Miscellaneous
Employees420
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Medifast (NYSE:MED) Frequently Asked Questions
What is Medifast's stock symbol?
Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."
How often does Medifast pay dividends? What is the dividend yield for Medifast?
Medifast declared a quarterly dividend on Thursday, June 13th. Investors of record on Friday, June 28th will be given a dividend of $0.75 per share on Wednesday, August 7th. This represents a $3.00 dividend on an annualized basis and a yield of 2.95%. The ex-dividend date of this dividend is Thursday, June 27th. View Medifast's Dividend History.
How were Medifast's earnings last quarter?
Medifast Inc (NYSE:MED) issued its earnings results on Thursday, August, 1st. The specialty retailer reported $1.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.71 by $0.04. The specialty retailer earned $187.10 million during the quarter, compared to analyst estimates of $181.74 million. Medifast had a net margin of 11.22% and a return on equity of 61.06%. Medifast's quarterly revenue was up 59.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.16 earnings per share. View Medifast's Earnings History.
When is Medifast's next earnings date?
What guidance has Medifast issued on next quarter's earnings?
Medifast updated its FY19 earnings guidance on Thursday, August, 1st. The company provided EPS guidance of $6.75-$6.95 for the period, compared to the Thomson Reuters consensus estimate of $6.78. The company issued revenue guidance of $730-$750 million, compared to the consensus revenue estimate of $738.02 million.
What price target have analysts set for MED?
2 Wall Street analysts have issued 12-month price targets for Medifast's stock. Their forecasts range from $130.00 to $216.00. On average, they expect Medifast's stock price to reach $173.00 in the next twelve months. This suggests a possible upside of 70.1% from the stock's current price. View Analyst Price Targets for Medifast.
What is the consensus analysts' recommendation for Medifast?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medifast.
Has Medifast been receiving favorable news coverage?
News coverage about MED stock has been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Medifast earned a news impact score of 2.5 on InfoTrie's scale. They also assigned news stories about the specialty retailer a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for Medifast.
Are investors shorting Medifast?
Medifast saw a increase in short interest in July. As of July 31st, there was short interest totalling 1,940,000 shares, an increase of 16.2% from the June 30th total of 1,669,200 shares. Based on an average daily trading volume, of 259,200 shares, the days-to-cover ratio is presently 7.5 days. Approximately 17.0% of the company's shares are sold short. View Medifast's Current Options Chain.
Who are some of Medifast's key competitors?
What other stocks do shareholders of Medifast own?
Who are Medifast's key executives?
Medifast's management team includes the folowing people:
- Mr. Daniel R. Chard, CEO & Director (Age 54)
- Mr. Timothy G. Robinson CPA, CPA, Chief Financial Officer (Age 57)
- Mr. William Baker IV, Exec. VP of Information Technology (Age 47)
- Mr. Nicholas Johnson, Exec. VP of Coach Success Market Pres of OPTAVIA USA (Age 39)
- Mr. Jason L. Groves, Exec. VP, Gen. Counsel & Corp. Sec. (Age 48)
Who are Medifast's major shareholders?
Medifast's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.43%), BlackRock Inc. (14.43%), Vanguard Group Inc. (12.44%), Renaissance Technologies LLC (5.83%), Hoplite Capital Management L.P. (3.45%) and Acadian Asset Management LLC (3.39%). Company insiders that own Medifast stock include Carl E Sassano, Charles P Connolly, Constance J Hallquist, Daniel R Chard, Glenn W Welling, Jeremy John Martin, Michael A Hoer, Michael C Macdonald, Ralph Rushton and Scott Schlackman. View Institutional Ownership Trends for Medifast.
Which institutional investors are selling Medifast stock?
MED stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, WINTON GROUP Ltd, Robeco Institutional Asset Management B.V., Man Group plc, Capital Fund Management S.A., Acadian Asset Management LLC, Balyasny Asset Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Medifast company stock in the last year include Carl E Sassano, Constance J Hallquist and Scott Schlackman. View Insider Buying and Selling for Medifast.
Which institutional investors are buying Medifast stock?
MED stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Hoplite Capital Management L.P., Pictet Asset Management Ltd., Pictet Asset Management Ltd., Victory Capital Management Inc., Royal Bank of Canada, Marshall Wace LLP and Allianz Asset Management GmbH. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard and Michael A Hoer. View Insider Buying and Selling for Medifast.
How do I buy shares of Medifast?
Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Medifast's stock price today?
One share of MED stock can currently be purchased for approximately $101.68.
How big of a company is Medifast?
Medifast has a market capitalization of $1.20 billion and generates $501 million in revenue each year. The specialty retailer earns $55.79 million in net income (profit) each year or $4.62 on an earnings per share basis. Medifast employs 420 workers across the globe.View Additional Information About Medifast.
What is Medifast's official website?
How can I contact Medifast?
Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]
MarketBeat Community Rating for Medifast (NYSE MED)
MarketBeat's community ratings are surveys of what our community members think about Medifast and other stocks. Vote "Outperform" if you believe MED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MED will underperform the S&P 500 over the long term. You may vote once every thirty days.
